SCHEMBL2214909

SCHEMBL2214909

NCc1cccc(C(=O)Nc2cccc(Nc3nc(-c4cccc5c4oc4ccccc45)cc4ccnn34)c2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 3/20 0.38
AURKB Q96GD4 1/20 0.36
MAPT P10636 4/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
LMNA P02545 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
LOX P28300 2/20 0.35
TP53 P04637 2/20 0.34
GAA P10253 1/20 0.34
F2RL3 Q96RI0 1/20 0.34
ROCK2 O75116 1/20 0.34
BRAF P15056 1/20 0.34
GALK1 P51570 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2215134 0.95 LOXL2 (0.38) LOXL2MAPTKDM4EALDH1A1HPGD
SCHEMBL2213715 0.94 SMN1; SMN2 (0.38) LOXL2MAPTKDM4EALDH1A1HPGD
SCHEMBL2215156 0.89 KDM4E (0.37) LOXL2MAPTKDM4EALDH1A1HPGD
SCHEMBL2214178 0.88 KDM4E (0.39) LOXL2MAPTKDM4EALDH1A1HPGD
SCHEMBL2215351 0.88 AURKB (0.36) LOXL2AURKBMAPTALDH1A1HPGD
SCHEMBL2211331 0.87 KDM4E (0.39) LOXL2MAPTKDM4EALDH1A1HPGD
SCHEMBL2214124 0.86 MAPT (0.49) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2213042 0.86 LMNA (0.37) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2215249 0.85 SMN1; SMN2 (0.37) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2216183 0.85 ALDH1A1 (0.42) LOXL2AURKBMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 LOXL2 3444/4885AURKB 1061/4885MAPT 3832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.